US-based pharmaceutical firm Zogenix has entered into a development and option agreement (D&O Agreement) with Altus Formulation (Altus) to develop abuse deterrent formulations of Zohydro ER (hydrocodone bitartrate) extended-release ...
Tags: Zogenix, Zohydro ER
Pharmaceutical companyc Food and Drug Administration (FDA) has approved Zohydro ER (hydrocodone bitartrate) extended-release capsules. Zohydro ER is an opioid agonist, extended-release oral formulation of hydrocodone without ...
US-based pharmaceutical company Zogenix has extended its co-marketing partnership with Battelle, for the DosePro needle-free drug delivery system through 29 March 2014. The partnership is focused on advancing out-licensing opportunities ...
The FDA has accepted the review of Zogenix new drug application (NDA) for Zohydro ER (hydrocodone bitartrate extended-release capsules) for the treatment of moderate to severe chronic pain. Zohydro ER is an oral, single-entity (without ...
Tags: Zohydro ER, hydrocodone bitartrate extended-release capsules
Zogenix has commenced first IND clinical trial for Relday in patients with chronic, stable schizophrenia or schizoaffective disorder. Relday is based on a combination of its DosePro needle-free, subcutaneous drug delivery system with a ...
Tags: Clinical Trial, DosePro needle-free drug, pharmacokinetic